With initial steps towards precision medicine in IHD [41–43], guided by the development of nano-particles for cell-specific drug delivery [44], a combined approach of NLRP3 inhibition in selected cell populations could reduce doses required to achieve therapeutic immunomodulation and thereby the susceptibility to infection [45]. The gene discussed is NLRP3; the disease is myocardial ischemia.